RecruitingNCT02617966
Ophthalmological
Cone-Rod Dystrophy
Also known as CRD, cone-rod degeneration, progressive cone dystrophy
Cone-Rod Dystrophy is a group of inherited retinal dystrophies in which cone photoreceptors are affected first and more severely than rods, distinguishing CRD from the rod-dominant pattern of retinitis pigmentosa. Patients typically present
ORPHA:1872 ↗Gene ABCA4Gene CNGB3Gene RPGR (multiple)Prevalence 1 per 30,000–40,000Onset First to second decade of lifeAutosomal recessive, autosomal dominant, X-linked
13
studies recruiting now
as of 7 Sept 2026
44
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
14 Jan 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT06789445
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
RecruitingPhase 1NCT04289571
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
RecruitingNot applicableNCT07341763
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
RecruitingNot applicableNCT03011541
Stem Cell Ophthalmology Treatment Study II
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 13 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Cone-Rod Dystrophy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: My Retina Tracker · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Cone-Rod Dystrophy
Cone-Rod Dystrophy is a group of inherited retinal dystrophies in which cone photoreceptors are affected first and more severely than rods, distinguishing CRD from the rod-dominant pattern of retinitis pigmentosa. Patients typically present in the first or second decade with decreased visual acuity and colour vision disturbances, followed by increasing photophobia and progressive peripheral vision loss as rod dysfunction develops. Genetic causation is highly heterogeneous, with pathogenic variants identified in over 30 genes, and clinical overlap with Stargardt disease (ABCA4-related CRD) and achromatopsia is common.
Common clinical features
Decreased central visual acuity, often the presenting symptomColour vision defects and colour discrimination difficultiesPhotophobia and hemeralopia (day blindness)Central scotomas on visual field testingMacular atrophy on fundus examinationProgressive peripheral visual field loss (later in disease course)Reduced or absent cone ERG responsesNystagmus in some patients
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Cone-Rod Dystrophy. Not eligibility rules; those are set by each study.
- A comprehensive retinal gene panel is essential before trial screening, as CRD is caused by many different genes and each trial targets a specific genetic defect.
- ERG findings distinguishing cone-primary vs. rod-primary dystrophy are used for eligibility confirmation; ensure recent electrophysiology records are available.
- Visual acuity eligibility windows are narrow in many trials; do not delay screening referral if your acuity is declining.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).